Press "Enter" to skip to content

Paxlovid tied to fewer COVID-19 hospitalizations, reduced risk of long COVID

A new retrospective cohort study conducted in Dubai shows that the antiviral nirmatrelvir plus ritonavir, sold as Paxlovid, is tied to a 61% reduction in COVID-19 hospitalization and a 58% lower rate of long COVID.